Bio-Techne Aktie

Bio-Techne EBITDA

EBITDA (Indtjening før renter, skatter, af- og nedskrivninger) for Bio-Techne (TECH) pr. 22. aug. 2026 er 251,89 Mio. USD. I foregående år var EBITDA (Indtjening før renter, skatter, af- og nedskrivninger) 138,27 Mio. USD — en ændring på 82,17 % (højere).

EBITDA

251,89 Mio.USD

YoY

82,17%

Senest opdateret:

EBITDA (Indtjening før renter, skatter, af- og nedskrivninger) for Bio-Techne er 2026 251,89 Mio. USD. EBITDA (Indtjening før renter, skatter, af- og nedskrivninger) for Bio-Techne var 2025 138,27 Mio. USD. Det falder dermed med 82,17% højere sammenlignet med året før.
Access this data via the Eulerpool API

Bio-Techne Aktieanalyse

Hvad laver Bio-Techne? Bio-Techne Corp is a global company specializing in the research and development of innovative products and solutions in the field of biosciences. The company was founded in 1976 in Minneapolis and was formerly known as Techne Corporation. Since then, it has grown into an internationally renowned company through its numerous acquisitions and mergers. The company is headquartered in Minneapolis, Minnesota, USA. The business philosophy of Bio-Techne Corp is to help bioscientific researchers and clinicians around the world perform their work more effectively, efficiently, and quickly. The company works closely with its customers to provide them with suitable products and services, thereby developing innovative solutions to the challenges in bioscience. Bio-Techne Corp has various business segments, including protein platforms, diagnostics, genetic analysis, clinical controls, cell culture products, and research reagents. Each business segment offers a variety of products and services to support researchers and clinicians in their work. A key business segment of Bio-Techne Corp is the protein platform, which offers a comprehensive range of proteins, antibodies, and corresponding detection reagents. The company is known for its high-quality proteins and antibodies, which contribute to improving the research of diseases such as cancer, diabetes, and neurological and immunological disorders. Another important business segment of Bio-Techne Corp is diagnostics. Here, the company offers a wide range of clinical diagnostic products, such as tests for analyzing urea, creatinine, and bone density. The company's products help clinicians make precise diagnoses and treat patients more effectively. The genetic analysis segment offers DNA sequencing, gene expression, and genome-wide analysis products and services. These tools enable researchers to better understand the functioning of the human body by exploring the underlying genetic changes. The clinical controls segment offers product and service offerings that improve the reliability and accuracy of diagnostic systems. The company works closely with medical facilities to provide diagnostic solutions that deliver fast and accurate results. The cell culture products segment offers a complete range of solutions for cell cultivation and growth. The offering ranges from basic nutrient media and additives to culture vessels and accessories. The company's products enable researchers to culture cells in a controlled environment and under precise conditions. The last segment of Bio-Techne Corp includes research reagents. Here, the company offers a wide range of reagents used for protein, antibody, and cell function analysis and research. The products meet the needs of researchers in modern bioscience. In summary, Bio-Techne Corp is a company specialized in developing innovative solutions in bioscience, advancing science and medicine. With its products and services offered in various sectors, the company successfully helps researchers and clinicians perform their work faster, more effectively, and cost-efficiently. Bio-Techne er et af de mest populære virksomheder på Eulerpool.com.

Hyppigt stillede spørgsmål om Bio-Techne aktie

EBITDA (Indtjening før renter, skatter, af- og nedskrivninger) for Bio-Techne er 251,89 Mio. USD i 2026.

EBITDA (Indtjening før renter, skatter, af- og nedskrivninger) for Bio-Techne ændrede sig fra 138,27 Mio. USD til 251,89 Mio. USD, hvilket repræsenterer en ændring på 82,17 %. Værdien er højere end i foregående år.

På Eulerpool kan du finde den fuldstændige historiske udvikling af EBITDA (Indtjening før renter, skatter, af- og nedskrivninger) Bio-Techne siden 2006 – med årlige værdier, diagrammer og detaljeret analyse.

EBITDA måler driftsresultatet før virkningen af finansieringsstruktur, skattesystem og ikke-kontante afskrivninger.

EBITDA = EBIT + Af- og nedskrivninger

EBITDA (Indtjening før renter, skatter, af- og nedskrivninger)s USD er en vigtig faktor for investorer. Ændringer i denne nøgletal kan signalere forbedrede eller forværrede fundamentale forhold, hvilket kan påvirke aktiekursen. På Eulerpool kan du følge EBITDA (Indtjening før renter, skatter, af- og nedskrivninger)s Bio-Techne historisk.

Access this data via the Eulerpool API

Resultatopgørelse — Bio-Techne

Alle nøgletal — Bio-Techne